cbdMD (YCBD) Cash from Operations Growth (1y) (2017 - 2025)
cbdMD (YCBD) Cash from Operations Growth (1y) (2017 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 81.06% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 8.26% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -46.22% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 63.59% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 73.78% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 33.73% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 16.88% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | cbdMD | 5.41 Mn | 3.29 Mn | 3.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -155.53% |
| Sep 30, 2025 | -243.84% |
| Jun 30, 2025 | -343.01% |
| Mar 31, 2025 | 73.09% |
| Dec 31, 2024 | -200.29% |
| Sep 30, 2024 | 163.52% |
| Jun 30, 2024 | 220.45% |
| Mar 31, 2024 | 59.39% |
| Dec 31, 2023 | 94.87% |
| Sep 30, 2023 | 86.32% |
| Jun 30, 2023 | 89.85% |
| Mar 31, 2023 | 66.67% |
| Dec 31, 2022 | 62.25% |
| Sep 30, 2022 | 55.57% |
| Jun 30, 2022 | 48.55% |
| Mar 31, 2022 | -75.81% |
| Dec 31, 2021 | -149.47% |
| Sep 30, 2021 | -1,019.20% |
| Jun 30, 2021 | -307.80% |
| Mar 31, 2021 | 30.76% |